Process promising for on-site printing of custom-dosed meds

October 4, 2017

(HealthDay)—Small molecular medicines can be printed precisely using organic vapor jets, according to a study published online Sept. 27 in Nature Communications.

Olga Shalev, Ph.D., from the University of Michigan in Ann Arbor, and colleagues discussed the potential use of solvent-free organic vapor jets to print small molecular medicines.

The researchers found that nanostructured films of small molecular pharmaceutical ingredients could be deposited by use of solvent-free printing; these ingredients included caffeine, acetaminophen, ibuprofen, tamoxifen, BAY 11-7082, and fluorescein. Accuracy was on the scale of µg per cm². The pharmaceutical ingredients could be printed onto glass, Tegaderm, Listerine tabs, and stainless steel microneedles. Similar crystallographic order and chemistry was demonstrated by the printed films and the original powders; relative to powder-form particles, controlled, order-of-magnitude enhancements of dissolution rate were observed. In vitro treatment of breast and ovarian cancer cell cultures in aqueous media by tamoxifen and BAY 11-7082 films showed similar behavior to drugs pre-dissolved in dimethyl sulfoxide.

"The ability to deposit small molecular drugs from their pure form, as and without the use of solvents as shown here, opens an alternative approach to drug screening and manufacturing, where accurate dosage, chemical and structural stability, and processing flexibility are needed without hindering functionality," the authors write. "The technique demonstrated here also potentially enables continuous manufacturing, eliminating the need for mixing and powder preparation."

Explore further: Eli Lilly develops continuous manufacturing process for chemotherapy drug

More information: Abstract/Full Text

Related Stories

Eli Lilly develops continuous manufacturing process for chemotherapy drug

June 16, 2017
Researchers at pharmaceutical giant Eli Lilly have developed a continuous manufacturing process for a chemotherapy drug, officials with the company recently announced. In their paper published in the journal Science, the ...

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.